Laureus Capital, a private equity firm, led a $26m Series B round Ethris, a biotechnology company. “Raising this Series B financing represents an important milestone for Ethris and validates the potential of our proprietary mRNA and LNP delivery platforms and the expert team we have built,” Carsten Rudolph, Ethris CEO.